ClinicalTrials.gg
CompletedNCT05375344MOVEONUPUpdated Nov 16, 2026

Mobility and Voiding Exercises in Older Women With Urinary Incontinence (MoVEonUp)

An interventional study of Exercise Group in Urinary Incontinence, Urge, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to female participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
70 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.

Enrollment
19th of 119
320 · median 75
Started
2022
with 8 others
No phase
72 of 135
10 open now
Registered
107th of 135
by date

Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 19th largest by enrollment of the 119 interventional ones that give a count, is one of 9 that started in 2022, is one of 72 with no phase, and was the 107th registered.

Urinary Incontinence, Urge

243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.

Browse Urinary Incontinence, Urge studies →

Open to participants now

19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 70 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Urinary Incontinence, Urge with a site in United States, or all of them as a file.
02

Study summary

A prospective, two-arm randomized clinical trial utilizing a multidimensional intervention to reduce falls in older women with Urinary Urge Incontinence. The intervention consist of general balance and strength training, bladder training and urge suppression, and home hazard assessments. The control group will receive informational booklets on fall prevention and behavioral treatment for urinary urge incontinence.

03

Conditions studied

  • Urinary Incontinence, Urge
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • 70 or older
  • Living independently in the community
  • Willingness to be randomized.
  • Ability to read and understand English
  • Be able to provide
  • Low physical activity (physically active for 30 minutes or more less than or equal to 2 days per week on average over the past 6 months) per PAS
  • Ambulatory (defined as patient not confined to bed or wheelchair OR ability to walk with or without an assistive device)
  • Self-reported moderate to severe urge-predominant UI based on the ICIQ-SF > 6 (Q 1+2+3)
  • Not planning to initiate new UI or overactive bladder (OAB) treatment during the study duration
  • Capable of participation in an exercise program without exacerbating any pre-existing condition(s), as determined by the study PI or designee

Exclusion criteria

Exclusion Criteria:

  • Pelvic organ prolapse passed the hymen (per patient report)
  • Undergoing active treatment for cancer (other than non-melanoma skin cancer)
  • Uncorrected visual or hearing loss.
  • Other urinary conditions or procedures that may affect continence status for example: urethral diverticulum, previous augmentation cystoplasty
  • Progressive neurodegenerative disease e.g. Parkinson's disease, multiple sclerosis per patient report
  • History of stroke or carotid sensitivity (i.e. syncopal falls) per patient report
  • Unstable cardiac disease per patient report
  • Fracture or joint replacement within the last six months per patient report
  • Significant cognitive impairment (defined as a modified TICs score of \< 27)
  • Per PI discretion, participant cannot enroll in study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Active comparator
    Exercise Group

    Participants in this group will participate in the home-based exercise group intervention that consists of general balance and strength training, bladder training and urge suppression, and home hazard assessments.

    Behavioral: Exercise Group

  • No intervention
    Control Group

    Participants in this group will receive informational booklets on fall prevention and behavioral treatment for Urgency Incontinence.

Interventions

  • BehavioralExercise Group

    Home-based exercise group intervention

06

What researchers measure

Primary outcomes

  1. Change in number of falls between the baseline visit and 1 year

    number of falls reported in a falls diary

    Time frame: 12 months

Secondary outcomes

  1. Change in urinary incontinence score on the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) between baseline visit and 1 year

    Change in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF). A minimum score is 0, a maximum score is 21 with a higher score indicating higher severity.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Andy UU, Newman DK, Wyman JF, Klusaritz H, Walsh W, Shou H, Koepler N, Schmitz KH, Reaves S, Arya L, Brown RT. The Mobility and Voiding Exercises in Older Women with Urinary Incontinence (MoVEonUp) randomized controlled trial: study protocol and rationale. BMC Geriatr. 2024 Dec 4;24(1):994. doi: 10.1186/s12877-024-05552-7. PubMed 39633261 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Nov 2026, 52 months.

Of 47 non-industry interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 52 months is above that.

Counting every sponsor, half of 77 studies reached it within 20 months; a quarter within 10 and three quarters within 41.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 16, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 16, 2022
StartActual
Jun 9, 2022
Primary completionActual
Nov 6, 2026was Sep 2026
CompletionActual
Nov 6, 2026was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Sep 2026→Nov 6, 2026 (actual)
moved 2 times, Oct 14, 2026 – Nov 16, 2026
Study completion
Sep 2026→Nov 6, 2026 (actual)
moved 2 times, Oct 14, 2026 – Nov 16, 2026
Enrollment
375 (estimated)→320 (actual)
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Nov 6, 2026 (now actual)
    Study completion Oct 2026→Nov 6, 2026 (now actual)
    Enrollment 375 (estimated)→320 (actual)
    + 1 other change: verification date
  2. Oct 14, 2026
    Primary completion Sep 2026→Oct 2026
    Study completion Sep 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05375344
Responsible party
Uduak Andy (Associate Professor, University of Pennsylvania) — Principal investigator
First posted
May 16, 2022
Start date
Jun 9, 2022
Primary completion
Nov 6, 2026
Completion
Nov 6, 2026
Last update
Nov 16, 2026

Study contacts

Uduak U Andy, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion